Cycle Checkpoint Abnormalities during Dementia: A Plausible Association with the Loss of Protection against Oxidative Stress in Alzheimer's Disease

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Katsel, Pavel ^a   Tan, Weilun ^a   Fam, Peter ^b   Purohit, Dushyant P ^a   Haroutunian, Vahram ^a,b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; ATR PROTEIN; BRCA1 PROTEIN; CHECKPOINT KINASE 1; PROTEIN MDMX; PROTEIN P53;

AEROBIC METABOLISM; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; CELL CYCLE; CELL CYCLE CHECKPOINT; CELL CYCLE REGULATION; COGNITIVE DEFECT; CONTROLLED STUDY; DEMENTIA; DISEASE COURSE; DISEASE SEVERITY; DNA DAMAGE; DOWN REGULATION; GENE EXPRESSION; GLYCOLYSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MICROARRAY ANALYSIS; MITOSIS; NERVE DEGENERATION; OXIDATIVE STRESS; POLYMERASE CHAIN REACTION; QUANTITATIVE ANALYSIS; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; TEMPORAL CORTEX;

ALZHEIMER DISEASE; AUTOPSY; CELL CYCLE CHECKPOINTS; DEMENTIA; DISEASE PROGRESSION; DNA DAMAGE; GENE REGULATORY NETWORKS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; OXIDATIVE STRESS; TEMPORAL LOBE; TRANSCRIPTOME;

EID: 84879835064     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0068361     Document Type: Article

References (85)

1. Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, et al. (2012) Correlation of Alzheimer's Disease Neuropathologic Changes with Cognitive Status: a Review of the Literature. J Neuropathol Exp Neurol 71: 362-381 10.1097/NEN.0b013e31825018f7 [doi].
2. McShea A, Harris PL, Webster KR, Wahl AF, Smith MA, (1997) Abnormal expression of the cell cycle regulators P16 and CDK4 in Alzheimer's disease. Am J Pathol 150: 1933-1939.
3. Nagy Z, Esiri MM, Cato AM, Smith AD, (1997) Cell cycle markers in the hippocampus in Alzheimer's disease. Acta Neuropathol 94: 6-15.
4. Smith TW, Lippa CF, (1995) Ki-67 immunoreactivity in Alzheimer's disease and other neurodegenerative disorders. J Neuropathol Exp Neurol 54: 297-303.
5. Liu DX, Greene LA, (2001) Neuronal apoptosis at the G1/S cell cycle checkpoint. Cell Tissue Res 305: 217-228.
6. Copani A, Condorelli F, Caruso A, Vancheri C, Sala A, et al. (1999) Mitotic signaling by beta-amyloid causes neuronal death. FASEB J 13: 2225-2234.
7. Chen Y, McPhie DL, Hirschberg J, Neve RL, (2000) The amyloid precursor protein-binding protein APP-BP1 drives the cell cycle through the S-M checkpoint and causes apoptosis in neurons. J Biol Chem 275: 8929-8935.
8. Andorfer C, Acker CM, Kress Y, Hof PR, Duff K, et al. (2005) Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms. J Neurosci 25: 5446-5454.
9. Zindy F, Cunningham JJ, Sherr CJ, Jogal S, Smeyne RJ, et al. (1999) Postnatal neuronal proliferation in mice lacking Ink4d and Kip1 inhibitors of cyclin-dependent kinases. Proc Natl Acad Sci U S A 96: 13462-13467.
10. Yang Y, Mufson EJ, Herrup K, (2003) Neuronal cell death is preceded by cell cycle events at all stages of Alzheimer's disease. J Neurosci 23: 2557-2563.
11. Mosch B, Morawski M, Mittag A, Lenz D, Tarnok A, et al. (2007) Aneuploidy and DNA replication in the normal human brain and Alzheimer's disease. J Neurosci 27: 6859-6867.
12. Lu PJ, Wulf G, Zhou XZ, Davies P, Lu KP, (1999) The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein [see comments]. Nature 399: 784-788.
13. Ogawa O, Lee HG, Zhu X, Raina A, Harris PL, et al. (2003) Increased p27, an essential component of cell cycle control, in Alzheimer's disease. Aging Cell 2: 105-110.
14. Evans TA, Raina AK, Delacourte A, Aprelikova O, Lee HG, et al. (2007) BRCA1 may modulate neuronal cell cycle re-entry in Alzheimer disease. Int J Med Sci 4: 140-145.
15. Harris PL, Zhu X, Pamies C, Rottkamp CA, Ghanbari HA, et al. (2000) Neuronal polo-like kinase in Alzheimer disease indicates cell cycle changes. Neurobiol Aging 21: 837-841. S0197458000002189 [pii].
16. Zhu X, McShea A, Harris PL, Raina AK, Castellani RJ, et al. (2004) Elevated expression of a regulator of the G2/M phase of the cell cycle, neuronal CIP-1-associated regulator of cyclin B, in Alzheimer's disease. J Neurosci Res 75: 698-703 10.1002/jnr.20028 [doi].
17. Tseng HC, Zhou Y, Shen Y, Tsai LH (2002) A survey of Cdk5 activator p35 and p25 levels in Alzheimer's disease brains. FEBS Lett 523: 58-62. S0014579302029344 [pii].
18. Previll LA, Crosby ME, Castellani RJ, Bowser R, Perry G, et al. (2007) Increased expression of p130 in Alzheimer disease. Neurochem Res 32: 639-644 ---10.1007/s11064-006-9146-3 [doi].
19. Ogawa O, Zhu X, Lee HG, Raina A, Obrenovich ME, et al. (2003) Ectopic localization of phosphorylated histone H3 in Alzheimer's disease: a mitotic catastrophe? Acta Neuropathol 105: 524-528 ---10.1007/s00401-003-0684-3 [doi]\.
20. Bajic VP, Su B, Lee HG, Kudo W, Siedlak SL, et al. (2011) Mislocalization of CDK11/PITSLRE, a regulator of the G2/M phase of the cell cycle, in Alzheimer disease. Cell Mol Biol Lett. 10.2478/s11658-011-0011-2 [doi].
21. Thakur A, Siedlak SL, James SL, Bonda DJ, Rao A, et al. (2008) Retinoblastoma protein phosphorylation at multiple sites is associated with neurofibrillary pathology in Alzheimer disease. Int J Clin Exp Pathol 1: 134-146.
22. Pei JJ, Grundke-Iqbal I, Iqbal K, Bogdanovic N, Winblad B, et al. (1998) Accumulation of cyclin-dependent kinase 5 (cdk5) in neurons with early stages of Alzheimer's disease neurofibrillary degeneration. Brain Res 797: 267-277.
23. Sultana R, Butterfield DA, (2007) Regional expression of key cell cycle proteins in brain from subjects with amnestic mild cognitive impairment. Neurochem Res 32: 655-662.
24. Bonda DJ, Evans TA, Santocanale C, Llosa JC, Vina J, et al. (2009) Evidence for the progression through S-phase in the ectopic cell cycle re-entry of neurons in Alzheimer disease. Aging (Albany NY) 1: 382-388.
25. Zhu X, Siedlak SL, Wang Y, Perry G, Castellani RJ, et al. (2008) Neuronal binucleation in Alzheimer disease hippocampus. Neuropathol Appl Neurobiol 34: 457-465 NAN908 [pii];-10.1111/j.1365-2990.2007.00908.x [doi].
26. Yang Y, Geldmacher DS, Herrup K, (2001) DNA replication precedes neuronal cell death in Alzheimer's disease. J Neurosci 21: 2661-2668.
27. Arendt T (2012) Cell Cycle Activation and Aneuploid Neurons in Alzheimer's Disease. Mol Neurobiol. 10.1007/s12035-012-8262-0 [doi].
28. McShea A, Lee HG, Petersen RB, Casadesus G, Vincent I, et al. (2007) Neuronal cell cycle re-entry mediates Alzheimer disease-type changes. Biochim Biophys Acta 1772: 467-472.
29. Conejero-Goldberg C, Townsend K, Davies P, (2008) Effects of cell cycle inhibitors on tau phosphorylation in N2aTau3R cells. J Mol Neurosci 35: 143-150 --10.1007/s12031-008-9044-z [doi].
30. Zhang J, Cicero SA, Wang L, Romito-Digiacomo RR, Yang Y, et al. (2008) Nuclear localization of Cdk5 is a key determinant in the postmitotic state of neurons. Proc Natl Acad Sci U S A 105: 8772-8777 0711355105 [pii];10.1073/pnas.0711355105 [doi].
31. Yang Y, Varvel NH, Lamb BT, Herrup K, (2006) Ectopic cell cycle events link human Alzheimer's disease and amyloid precursor protein transgenic mouse models. J Neurosci 26: 775-784.
32. Kallhoff-Munoz V, Hu L, Chen X, Pautler RG, Zheng H, (2008) Genetic dissection of gamma-secretase-dependent and-independent functions of presenilin in regulating neuronal cell cycle and cell death. J Neurosci 28: 11421-11431 28/44/11421 [pii];-10.1523/JNEUROSCI.2873-08.2008 [doi].
33. Herrup K (2012) The contributions of unscheduled neuronal cell cycle events to the death of neurons in Alzheimer's disease. Front Biosci (Elite Ed) 4: 2101-2109. 527 [pii].
34. Savitsky K, Bar-Shira A, Gilad S, Rotman G, Ziv Y, et al. (1995) A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science 268: 1749-1753.
35. Shiloh Y, Rotman G, (1996) Ataxia-telangiectasia and the ATM gene: linking neurodegeneration, immunodeficiency, and cancer to cell cycle checkpoints. J Clin Immunol 16: 254-260.
36. Cosentino C, Grieco D, Costanzo V, (2011) ATM activates the pentose phosphate pathway promoting anti-oxidant defence and DNA repair. EMBO J 30: 546-555 emboj2010330 [pii];10.1038/emboj.2010.330 [doi].
37. Green DR, Chipuk JE, (2006) p53 and metabolism: Inside the TIGAR. Cell 126: 30-32 S0092-8674(06)00825-7 [pii];10.1016/j.cell.2006.06.032 [doi].
38. Bensaad K, Tsuruta A, Selak MA, Vidal MN, Nakano K, et al. (2006) TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 126: 107-120 S0092-8674(06)00762-8 [pii];10.1016/j.cell.2006.05.036 [doi].
39. Prabakaran S, Swatton JE, Ryan MM, Huffaker SJ, Huang JJ, et al. (2004) Mitochondrial dysfunction in Schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol Psychiatry 9: 684-697.
40. Katsel P, Davis KL, Li C, Tan W, Greenstein E, et al. (2008) Abnormal Indices of Cell Cycle Activity in Schizophrenia and their Potential Association with Oligodendrocytes. Neuropsychopharmacology 33: 2993-3009.
41. Benes FM, Lim B, Subburaju S, (2009) Site-specific regulation of cell cycle and DNA repair in post-mitotic GABA cells in schizophrenic versus bipolars. Proc Natl Acad Sci U S A 106: 11731-11736 0903066106 [pii];10.1073/pnas.0903066106 [doi].
42. Katsel P, Li C, Haroutunian V, (2007) Gene Expression Alterations in the Sphingolipid Metabolism Pathways during Progression of Dementia and Alzheimer's Disease: A Shift Toward Ceramide Accumulation at the Earliest Recognizable Stages of Alzheimer's Disease? Neurochem Res 32: 845-856.
43. Herzog KH, Chong MJ, Kapsetaki M, Morgan JI, McKinnon PJ, (1998) Requirement for Atm in ionizing radiation-induced cell death in the developing central nervous system. Science 280: 1089-1091.
44. Stewart GS, Maser RS, Stankovic T, Bressan DA, Kaplan MI, et al. (1999) The DNA double-strand break repair gene hMRE11 is mutated in individuals with an ataxia-telangiectasia-like disorder. Cell 99: 577-587. S0092-8674(00)81547-0 [pii].
45. Girard PM, Riballo E, Begg AC, Waugh A, Jeggo PA, (2002) Nbs1 promotes ATM dependent phosphorylation events including those required for G1/S arrest. Oncogene 21: 4191-4199 10.1038/sj.onc.1205596 [doi].
46. Lu T, Pan Y, Kao SY, Li C, Kohane I, et al. (2004) Gene regulation and DNA damage in the ageing human brain. Nature 429: 883-891.
47. Rass U, Ahel I, West SC, (2007) Defective DNA repair and neurodegenerative disease. Cell 130: 991-1004 S0092-8674(07)01141-5 [pii];10.1016/j.cell.2007.08.043 [doi].
48. Cotman CW, Su JH, (1996) Mechanisms of neuronal death in Alzheimer's disease. Brain Pathol 6: 493-506.
49. Mullaart E, Boerrigter ME, Ravid R, Swaab DF, Vijg J, (1990) Increased levels of DNA breaks in cerebral cortex of Alzheimer's disease patients. Neurobiol Aging 11: 169-173.
50. Chen J, Cohen ML, Lerner AJ, Yang Y, Herrup K, (2010) DNA damage and cell cycle events implicate cerebellar dentate nucleus neurons as targets of Alzheimer's disease. Mol Neurodegener 5: 60 1750-1326-5-60 [pii];--10.1186/1750-1326-5-60 [doi].
51. Hooper C, Meimaridou E, Tavassoli M, Melino G, Lovestone S, et al. (2007) p53 is upregulated in Alzheimer's disease and induces tau phosphorylation in HEK293a cells. Neurosci Lett 418: 34-37 S0304-3940(07)00291-1 [pii];10.1016/j.neulet.2007.03.026 [doi].
52. Kitamura Y, Shimohama S, Kamoshima W, Matsuoka Y, Nomura Y, et al. (1997) Changes of p53 in the brains of patients with Alzheimer's disease. Biochem Biophys Res Commun 232: 418-421 S0006-291X(97)96301-4 [pii];10.1006/bbrc.1997.6301 [doi].
53. de la Monte SM, Sohn YK, Wands JR (1997) Correlates of p53- and Fas (CD95)-mediated apoptosis in Alzheimer's disease. J Neurol Sci 152: 73-83. S0022-510X(97)00131-7 [pii].
54. Di DF, Cenini G, Sultana R, Perluigi M, Uberti D, et al. (2009) Glutathionylation of the pro-apoptotic protein p53 in Alzheimer's disease brain: implications for AD pathogenesis. Neurochem Res 34: 727-733 ---10.1007/s11064-009-9924-9 [doi].
55. Uberti D, Lanni C, Racchi M, Govoni S, Memo M, (2008) Conformationally altered p53: a putative peripheral marker for Alzheimer's disease. Neurodegener Dis 5: 209-211 000113704 [pii];10.1159/000113704 [doi].
56. Madan E, Gogna R, Kuppusamy P, Bhatt M, Pati U, et al. (2012) TIGAR induces p53-mediated cell-cycle arrest by regulation of RB-E2F1 complex. Br J Cancer 107: 516-526 bjc2012260 [pii];10.1038/bjc.2012.260 [doi].
57. Kerns DC, Vong GS, Barley K, Dracheva S, Katsel P, et al. (2010) Gene expression abnormalities and oligodendrocyte deficits in the internal capsule in schizophrenia. Schizo Res 120: 150-158.
58. Barley K, Dracheva S, Byne W, (2009) Subcortical oligodendrocyte- and astrocyte-associated gene expression in subjects with schizophrenia, major depression and bipolar disorder. Schizophr Res 112: 54-64 S0920-9964(09)00176-5 [pii];10.1016/j.schres.2009.04.019 [doi].
59. Yurov YB, Vostrikov VM, Vorsanova SG, Monakhov VV, Iourov IY, (2001) Multicolor fluorescent in situ hybridization on post-mortem brain in schizophrenia as an approach for identification of low-level chromosomal aneuploidy in neuropsychiatric diseases. Brain Dev 23Suppl 1: 186-190.
60. Yurov YB, Iourov IY, Vorsanova SG, Demidova IA, Kravetz VS, et al. (2008) The schizophrenia brain exhibits low-level aneuploidy involving chromosome 1. Schizophr Res 98: 139-147 S0920-9964(07)00329-5 [pii];10.1016/j.schres.2007.07.035 [doi].
61. Sourlingas TG, Issidorides MR, Alevizos B, Kontaxakis VP, Chrysanthou-Piterou M, et al. (2003) Lymphocytes from bipolar and schizophrenic patients share common biochemical markers related to histone synthesis and histone cell membrane localization characteristic of an activated state. Psychiatry Res 118: 55-67.
62. Middleton FA, Mirnics K, Pierri JN, Lewis DA, Levitt P, (2002) Gene expression profiling reveals alterations of specific metabolic pathways in schizophrenia. J Neurosci 22: 2718-2729.
63. Maurer I, Zierz S, Moller H (2001) Evidence for a mitochondrial oxidative phosphorylation defect in brains from patients with schizophrenia. Schizophr Res 48: 125-136. S092099640000075X [pii].
64. Benes FM, Walsh J, Bhattacharyya S, Sheth A, Berretta S, (2003) DNA fragmentation decreased in schizophrenia but not bipolar disorder. Arch Gen Psychiatry 60: 359-364.
65. Haroutunian V, Perl DP, Purohit DP, Marin D, Khan K, et al. (1998) Regional distribution of neuritic plaques in the nondemented elderly and subjects with very mild Alzheimer disease. Arch Neurol 55: 1185-1191.
66. Davis KL, Mohs RC, Marin D, Purohit DP, Perl DP, et al. (1999) Cholinergic markers in elderly patients with early signs of Alzheimer disease. JAMA 281: 1401-1406.
67. Naslund J, Haroutunian V, Mohs R, Davis KL, Davies P, et al. (2000) Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA 283: 1571-1577.
68. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, et al. (1991) The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 41: 479-486.
69. Purohit DP, Perl DP, Haroutunian V, Powchik P, Davidson M, et al. (1998) Alzheimer disease and related neurodegenerative diseases in elderly patients with schizophrenia: a postmortem neuropathologic study of 100 cases. Arch Gen Psychiatry 55: 205-211.
70. Morris JC, (1993) The clinical dementia rating (CDR): current version and scoring rules. Neurology 43: 2412-2414.
71. Dooneief G, Marder K, Tang MX, Stern Y, (1996) The Clinical Dementia Rating scale: community-based validation of "profound' and "terminal' stages. Neurology. 46: 1746-1749.
72. Fillenbaum GG, Peterson B, Morris JC, (1996) Estimating the validity of the clinical Dementia Rating Scale: the CERAD experience. Consortium to Establish a Registry for Alzheimer's Disease. Aging (Milano) 8: 379-385.
73. Haroutunian V, Schnaider-Beeri M, Schmeidler J, Wysocki M, Purohit DP, et al. (2008) Role of the neuropathology of Alzheimer disease in dementia in the oldest-old. Arch Neurol 65: 1211-1217.
74. Haroutunian V, Purohit DP, Perl DP, Marin D, Khan K, et al. (1999) Neurofibrillary tangles in nondemented elderly subjects and mild Alzheimer disease. Arch Neurol 56: 713-718.
75. Mirra SS, Vogel FS, Heyman A (1987) Guide to the CERAD protocol for the neuropathological assessment of Alzheimer's disease. CERAD.
76. Braak H, Braak E, (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl) 82: 239-259.
77. Haroutunian V, Katsel P, Schmeidler J (2009) Transcriptional vulnerability of brain regions in Alzheimer's disease and dementia. Neurobiol Aging 30: 561-573. PMID: 17845826.
78. Haroutunian V, Katsel P, Dracheva S, Davis KL, (2006) The Human Homolog of QKI Gene Affected in the Severe Dysmyelination "Quaking" Mouse Phenotype is Downregulated in Multiple Brain Regions in Schizophrenia. Am J Psychiat 163: 1834-1837.
79. Katsel P, Davis KL, Gorman JM, Haroutunian V, (2005) Variations in differential gene expression patterns across multiple brain regions in schizophrenia. Schizo Res 77: 241-252.
80. Katsel P, Davis KL, Haroutunian V, (2005) Variations in myelin and oligodendrocyte-related gene expression across multiple brain regions: A gene ontology study. Schizo Res 79: 157-173.
81. Benjamini Y, Hochberg Y, (1995) Controlling the false discovery rate- a practical and powerful approach to multiple testing. Journal of the Royal Society Series B (Methodology) 57: 289-300.
82. Katsel P, Tan W, Haroutunian V, (2009) Gain in Brain Immunity in the Oldest-Old Differentiates Cognitively Normal from Demented Individuals. PloS ONE 4: e7642-1-e7642-15.
83. Budhraja V, Spitznagel E, Schaiff WT, Sadovsky Y, (2003) Incorporation of gene-specific variability improves expression analysis using high-density DNA microarrays. BMC Biol 1: 1.
84. Mariani TJ, Budhraja V, Mecham BH, Gu CC, Watson MA, et al. (2003) A variable fold change threshold determines significance for expression microarrays. FASEB J 17: 321-323.
85. Ekins S, Andreyev S, Ryabov A, Kirillov E, Rakhmatulin EA, et al. (2006) A combined approach to drug metabolism and toxicity assessment. Drug Metab Dispos 34: 495-503 dmd.105.008458 [pii];10.1124/dmd.105.008458 [doi].